Patrex

RSS

sildenafil

Withdrawn
This medicine is now withdrawn from use in the European Union.

Overview

The marketing authorisation for Patrex has not been renewed by the marketing authorisation holder and is now withdrawn.

This EPAR was last updated on 18/08/2005

Authorisation details

Product details
Name
Patrex
Agency product number
EMEA/H/C/000204
Active substance
sildenafil
International non-proprietary name (INN) or common name
sildenafil
Therapeutic area (MeSH)
Erectile Dysfunction
Anatomical therapeutic chemical (ATC) code
G04BE03
Publication details
Marketing-authorisation holder
Pfizer Limited
Revision
4
Date of issue of marketing authorisation valid throughout the European Union
15/09/1998
Contact address
Ramsgate Road
Sandwich
Kent
CT13 9NJ
United Kingdom

Product information

15/09/2003 Patrex - EMEA/H/C/000204 -

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Urologicals

Therapeutic indication

Treatment of men with erectile dysfunction, which is the inability to achieve or maintain a penile
erection sufficient for satisfactory sexual performance.
In order for Patrex to be effective, sexual stimulation is required.
PATREX is not indicated for use by women.

How useful was this page?

Add your rating
Average
1 rating
1 rating